GlobeNewswire BiotechnologyQwen · 实盘不做把握 9/10不做原因:不是事件
北京时间·🕒 发布 19:00:00·⟳ 抓取 19:01:14·⚡ 决策 09-01 19:13:15 +12m01s·56.1 天前
Monte Rosa Therapeutics宣布管理层将参加两场投资者会议（Wells Fargo及Morgan Stanley医疗大会）
该公告为Monte Rosa Therapeutics的例行投资者会议参与通知，仅披露管理层将出席两场行业会议的时间安排，不含任何新增临床、商业、财务或监管信息，属于完全无催化价值的例行IR公告，无任何可交易方向。
📄 原文GlobeNewswire Biotechnology↗ 原文
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology…
不做 Monte Rosa Therapeutics（GLUE.US）
公告为例行投资者会议出席通知，不含任何新增实质性信息（无临床数据、无合作、无财务变化、无监管进展），不构成任何方向催化，无edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Monte Rosa Therapeutics发布GlobeNewswire公告，宣布CEO将于9月10日参加Wells Fargo医疗大会炉边对话、9月14日参加Morgan Stanley全球医疗大会。公告全文仅涉及会议出席安排和webcast链接，无任何新增管线数据、合作关系、财务指引或监管信息。此类会议参与公告是上市公司最常见的例行IR披露，不含任何增量事实，无法构成任何方向的交易催化。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无
方向:无适用先例
涨幅量级:无
形态:无
原文全文
展开原文 · 1,847 字
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) --
Monte Rosa Therapeutics, Inc.
(Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:
Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 10, 2026, at 12:45 p.m. ET
Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY) – September 14, 2026
A webcast of the fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s website at
ir.monterosatx.com
, and archived versions will be made available for 30 days following the presentations.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit
www.monterosatx.com
.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
Monte Rosa Therapeutics, Inc.
(Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:
Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 10, 2026, at 12:45 p.m. ET
Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY) – September 14, 2026
A webcast of the fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s website at
ir.monterosatx.com
, and archived versions will be made available for 30 days following the presentations.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit
www.monterosatx.com
.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。